Literature DB >> 27306302

Generic medications for hepatitis C.

Donald M Jensen1, Phoebe Sebhatu1, Nancy S Reau1.   

Abstract

The recent development and approval of expensive but highly effective oral agents against hepatitis C has led to restrictions and access limitations in many countries with limited healthcare budgets. Generic formulations of many of these agents are available at a fraction of the retail price in several countries because of generic licensure agreements. The discounted alternatives are only accessible in developing countries and require manufacturing and distribution regulations to ensure the quality and bioequivalence of the new drug formulations. The continued medication access limitations have driven great interest in the practice of personal drug importation of the generic formulations. This review and debate will address the medical and legal issues involved in the purchase and importation of these medicines.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords:  counterfeit; generic; hepatitis C; regulations

Mesh:

Substances:

Year:  2016        PMID: 27306302     DOI: 10.1111/liv.13120

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.

Authors:  Aung H Bwa; Gayatri Nangia; Si T S Win; Soe T Maung; Khin A W Han; Su S Htar; Lei Y Wine; Wint W Ko; Moe P Oo; Naomi K T Hlaing; Julia Palecki; Bao L Loza; Khin M Win; Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2018-12-19

2.  The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.

Authors:  Andrew M Hill; Sanjay Nath; Bryony Simmons
Journal:  J Virus Erad       Date:  2017-07-01

Review 3.  Hepatitis C treatment: where are we now?

Authors:  Nicholas J Burstow; Zameer Mohamed; Asmaa I Gomaa; Mark W Sonderup; Nicola A Cook; Imam Waked; C Wendy Spearman; Simon D Taylor-Robinson
Journal:  Int J Gen Med       Date:  2017-02-17

4.  Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.

Authors:  Raffaella Ravinetto; Anja De Weggheleire; Thomas P C Dorlo; Sven Francque; An Sokkab; Corinne Pouget; Bruno Meessen; Patricia Tabernero; Paul N Newton; Lut Lynen
Journal:  Trop Med Int Health       Date:  2016-10-17       Impact factor: 2.622

5.  High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C.

Authors:  Andrew Hill; Giten Khwairakpam; James Wang; Sergey Golovin; Julia Dragunova; Rachel Smith; Vicky Houghton-Price; Roxanna Korologou-Linden; Sanjay Nath; Anna Savage; Greg Jefferys
Journal:  J Virus Erad       Date:  2017-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.